What Does Genomind Do?

Total employees67
HeadquartersKing of Prussia
Founded

Genomind is a specialized mental health care company focused on pharmacogenomic testing. In February 2024, Myriad Genetics acquired select assets from Genomind, including its flagship products like the Genecept Assay® and Genomind® Professional PGx Express™. These tools analyze key genes influencing an individual's response to psychiatric medications, providing clinicians with actionable insights for personalized treatment strategies. The goal is to reduce trial-and-error in medication selection, thereby improving patient outcomes. The Genomind brand and its associated tests, now part of Myriad Genetics, continue to serve clinicians and patients, aiming to bridge genetics and mental health with data-driven information.

Where Is Genomind's Headquarters?

HQ Function

The King of Prussia facility historically served as the central hub for Genomind's operations, including research and development, CLIA-certified laboratory services, customer support, and corporate administration. These functions related to Genomind products are now part of Myriad Genetics.

Notable Features:

The facility is situated in a modern office park, likely equipped with state-of-the-art laboratory facilities for genetic testing and analysis. Its location offers proximity to other life science companies and research institutions.

Work Culture:

The work culture historically associated with Genomind likely emphasized innovation, scientific rigor, collaboration, and a patient-centric approach, driven by its mission to improve mental health care. This ethos is expected to carry forward within Myriad Genetics' mental health division.

HQ Significance:

King of Prussia's location in the Greater Philadelphia area provides access to a rich talent pool in biotechnology, pharmaceuticals, and healthcare, as well as proximity to leading academic and research institutions, fostering innovation and partnerships relevant to pharmacogenomics.

Values Reflected in HQ: The choice of a modern, well-equipped facility in a biotech hub reflected Genomind's commitment to cutting-edge science, professional excellence, and innovation in mental healthcare, values that align with Myriad Genetics' mission.

Location:

While Genomind's primary physical operations and laboratory were historically based in the United States, its services reached patients and clinicians in the U.S. and Canada. Following the acquisition of its key assets by Myriad Genetics, these products continue to be available in these markets. Myriad Genetics has a broader global presence, which may influence the future reach of Genomind's pharmacogenomic solutions. Genomind's research has also contributed to the global understanding of pharmacogenomics in mental health through publications and educational initiatives.

Street Address:

2200 Renaissance Blvd, Suite 100

City:

King of Prussia

State/Province:

PA

Country:

USA

Where Else Does Genomind Operate Around the World?

No additional office locations available.

Buying Intent Signals for Genomind

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Genomind? Meet the Executive Team

As of April 2025, Genomind' leadership includes:

Shawn Patrick O'Brien - Chief Executive Officer (at time of acquisition)
Stephen M. Smith - Chief Financial Officer (at time of acquisition)
Stacey C. Ciano - Chief Commercial Officer (at time of acquisition)
Marna S. Barr, M.Ed. - Chief Operating Officer (at time of acquisition)
Kenneth M. Certa, MD - Chief Medical Officer, Medical Affairs (at time of acquisition)
Margaret M. Rano, MS - Chief Compliance Officer, VP of Quality Assurance & Regulatory Affairs (at time of acquisition)

Who's Investing in Genomind?

Genomind has been backed by several prominent investors over the years, including:

Key assets acquired by Myriad Genetics (February 2024).
Historically funded by investors including Rex Health Ventures, Signet Healthcare Partners, and GHI Capital Partners.

What Leadership Changes Has Genomind Seen Recently?

Hire0
Exits0

The most significant event impacting Genomind's executive structure was the acquisition of its key assets by Myriad Genetics in February 2024. Leadership for the Genomind product lines is now integrated within Myriad Genetics. Specific executive movements for the Genomind-branded unit post-acquisition under Myriad are not typically publicized as distinct Genomind announcements.

What Technology (Tech Stack) Is Used byGenomind?

Discover the tools Genomind uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Genomind Email Formats and Examples

Prior to its asset acquisition by Myriad Genetics, Genomind likely utilized common corporate email formats. A frequently observed pattern for companies of its type is the first initial followed by the last name. Email communications regarding Genomind products and services would now typically originate from Myriad Genetics email domains.

[first_initial][last]@genomind.com

Format

jdoe@genomind.com

Example

80%

Success rate

What's the Latest News About Genomind?

Myriad GeneticsFebruary 29, 2024

Myriad Genetics Completes Acquisition of Select Assets from Genomind

Myriad Genetics announced the completion of its acquisition of key assets from Genomind, Inc., including the Genecept Assay®, Genomind Professional PGx Express™ test, and Genomind Mental Health Map™. This strategic acquisition aims to enhance Myriad's mental health offerings and expand patient access to precision medicine....more

Business WireOctober 4, 2023

Genomind and Albertsons Companies Collaborate to Increase Patient Access to Pharmacogenomic Testing and Improve Mental Health Outcomes

Genomind announced a collaboration with Albertsons Companies to make its pharmacogenomic (PGx) testing services more accessible to patients through Albertsons' extensive network of pharmacies. The partnership aimed to empower pharmacists and patients with genetic insights for medication management in mental health....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Genomind, are just a search away.